Mallinckrodt Plc filed a lawsuit against the U.S. Department of Health and Human Services and forecast an about 10 percent hit to annual net sales of the company’s gel used to treat multiple sclerosis symptoms following changes to Medicaid rebate calculations, sending shares plunging as much as 34 percent.
The U.S. Supreme Court on Monday handed a victory to Merck & Co. – at least for now – by throwing out a lower court ruling that had revived hundreds of lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking the osteoporosis drug Fosamax.
The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found.
Bayer shares fell by as much as 5 percent after a California couple were awarded more than $2 billion in the largest U.S. jury penalty over allegations the company’s Roundup weed killer causes cancer.
A California jury awarded more than $2 billion to a couple who claimed Bayer AG’s glyphosate-based Roundup weed killer caused their cancer, in the largest U.S. jury verdict to date against the company in litigation over the chemical.
Teva and Novartis’ Sandoz are contesting charges stemming from a multi-state lawsuit alleging that a number of generic drugmakers conspired to manipulate prices on more than 100 drugs.
Novartis said claims of price fixing against the drugmaker’s Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit.
Drug distributor McKesson Corp. agreed to pay $37 million to resolve a lawsuit by the state of West Virginia seeking to hold the company responsible for contributing to the opioid epidemic, the state’s attorney general said.
With a goal of eradicating hepatitis C, NHS England has teamed up Gilead Sciences Inc., Merck & Co. and AbbVie Inc.
Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.